{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:45:26Z","timestamp":1788057926638,"version":"build-2784847793"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Reasons for the relatively poor performance of bleeding prediction models are not well understood but may relate to differences in predictors for various anatomical sites of bleeding.<\/jats:p><jats:p>\n          Methods\u2003We pooled individual participant data from four randomized controlled trials of antithrombotic therapy in patients with coronary and peripheral artery diseases, embolic stroke of undetermined source (ESUS), or atrial fibrillation. We examined discrimination and calibration of models for any major bleeding, major gastrointestinal (GI) bleeding, and intracranial hemorrhage (ICH), according to the time since initiation of antithrombotic therapy, and indication for antithrombotic therapy.<\/jats:p><jats:p>\n          Results\u2003Of 57,813 patients included, 1,948 (3.37%) experienced major bleeding, including 717 (1.24%) major GI bleeding and 274 (0.47%) ICH. The model derived to predict major bleeding at 1 year from any site (c-index, 0.69, 95% confidence interval [CI], 0.68\u20130.71) performed similarly when applied to predict major GI bleeding (0.71, 0.69\u20130.74), but less well to predict ICH (0.64, 0.61\u20130.69). Models derived to predict GI bleeding (0.75, 0.74\u20130.78) and ICH (0.72, 0.70\u20130.79) performed better than the general major bleeding model. Discrimination declined over time since the initiation of antithrombotic treatment, stabilizing at approximately 2 years for any major bleeding and major GI bleeding and 1 year for ICH. Discrimination was best for the model predicting ICH in the ESUS population (0.82, 0.78\u20130.92) and worst for the model predicting any major bleeding in the coronary and peripheral artery disease population (0.66, 0.65\u20130.69).<\/jats:p><jats:p>\n          Conclusion\u2003Performance of risk prediction models for major bleeding is affected by site of bleeding, time since initiation of antithrombotic therapy, and indication for antithrombotic therapy.<\/jats:p>","DOI":"10.1055\/a-2259-1134","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T23:54:41Z","timestamp":1706831681000},"page":"e121-e131","source":"Crossref","is-referenced-by-count":4,"title":["Bleeding Risk Prediction in Patients Treated with Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation"],"prefix":"10.1055","volume":"08","author":[{"given":"Vinai","family":"Bhagirath","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"},{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Kovalova","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant I.","family":"Bangdiwala","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"},{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"},{"name":"University of Galway, Galway, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Shoamanesh","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"},{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Coppolecchia","sequence":"additional","affiliation":[{"name":"Bayer US LLC, Whippany, New Jersey, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsiana","family":"Vaitsiakhovich","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kleinjung","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardi","family":"Mundl","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"},{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"07","key":"ref1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4244\/EIJ-D-20-01197","article-title":"Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis","volume":"17","author":"R Piccolo","year":"2021","journal-title":"EuroIntervention"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"757087","DOI":"10.3389\/fcvm.2021.757087","article-title":"Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"X Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"20","key":"ref3","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJM199905203402007","article-title":"Vascular-bed\u2013specific hemostasis and hypercoagulable states","volume":"340","author":"R D Rosenberg","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"ref4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"J W Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"ref5","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"R G Hart","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"S J Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/17407745221149222","article-title":"A hybrid automated event adjudication system for clinical trials","volume":"20","author":"F Yuan","year":"2023","journal-title":"Clin Trials"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"K Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"J P Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/oxfordjournals.aje.a115101","article-title":"The impact of confounder selection criteria on effect estimation","volume":"129","author":"R M Mickey","year":"1989","journal-title":"Am J Epidemiol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/sim.3378","article-title":"Measures to assess the prognostic ability of the stratified Cox proportional hazards model","volume":"28","author":"Fibrinogen Studies Collaboration","year":"2009","journal-title":"Stat Med"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/sim.8570","article-title":"Graphical calibration curves and the integrated calibration index (ICI) for survival models","volume":"39","author":"P C Austin","year":"2020","journal-title":"Stat Med"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal validation of predictive models: efficiency of some procedures for logistic regression analysis","volume":"54","author":"E W Steyerberg","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"issue":"46","key":"ref17","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"E C O'Brien","year":"2015","journal-title":"Eur Heart J"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"e017157","DOI":"10.1136\/bmjopen-2017-017157","article-title":"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation","volume":"7","author":"K AA Fox","year":"2017","journal-title":"BMJ Open"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"M C Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"B F Gage","year":"2006","journal-title":"Am Heart J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Z Hijazi","year":"2016","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"g4606","DOI":"10.1136\/bmj.g4606","article-title":"Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores","volume":"349","author":"J Hippisley-Cox","year":"2014","journal-title":"BMJ"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"e0197583","DOI":"10.1371\/journal.pone.0197583","article-title":"Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis","volume":"13","author":"R CP Makam","year":"2018","journal-title":"PLoS One"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s12028-022-01671-4","article-title":"Risk factors for anticoagulant-associated intracranial hemorrhage: a systematic review and meta-analysis","volume":"38","author":"Z Zeng","year":"2023","journal-title":"Neurocrit Care"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/gut.2010.228437","article-title":"Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit","volume":"60","author":"S A Hearnshaw","year":"2011","journal-title":"Gut"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/STROKEAHA.120.032550","article-title":"Intracerebral hemorrhage incidence, mortality, and association with oral anticoagulation use: a population study","volume":"52","author":"S M Fernando","year":"2021","journal-title":"Stroke"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jacc.2019.07.065","article-title":"Major bleeding in patients with coronary or peripheral artery disease treated with rivaroxaban plus aspirin","volume":"74","author":"J W Eikelboom","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1474-4422(21)00024-7","article-title":"Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies","volume":"20","author":"J G Best","year":"2021","journal-title":"Lancet Neurol"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2259-1134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:12:44Z","timestamp":1730812364000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2259-1134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":27,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2259-1134","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2024,1]]}}}